Spectinomycin dihydrochloride pentahydrate

Research use only, not for human use.

Spectinomycin dihydrochloride pentahydrate is an antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.

Spectinomycin dihydrochloride pentahydrate is an antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.(In Vitro):Spectinomycin dihydrochloride pentahydrate selectively inhibits protein synthesis in cells and in extracts of Escherichia coli:Spectinomycin dihydrochloride pentahydrate (50 μg/mL) inhibits Escherichia coli growth rapidly and reversibly, and suppresses amino acid incorporation immediately.Spectinomycin dihydrochloride pentahydrate (1 μg/mL or 3 μM) inhibits polypeptide synthesis directed either by endogenous messenger RNA or by MS-2 bacteriophage RNA, with maximum inhibition of 70-80% in extracts of Escherichia coli.Spectinomycin dihydrochloride pentahydrate blocks the translocation of peptidyl-tRNAs from A-site to P-site by inhibiting the binding of elongation factor G to the ribosome.Spectinomycin dihydrochloride pentahydrate interacts specifically with the residues G1064 and 01192 in 16S rRNA and potentially makes it inactive.Spectinomycin dihydrochloride pentahydrate exhibits splicing inhibition and dependent on pH changes and Mg2+ concentration, indicating electrostatic interactions with the intron RNA.(In Vivo):Spectinomycin dihydrochloride pentahydrate (20 mg/kg; i.m.; 20-100 mg/kg; 9 d) shows the safety in healthy chicks.Spectinomycin dihydrochloride pentahydrate (10 mg/kg; i.v.; single dose) has the major elimination pathway by renal excretion, approximately 55% is excreted into the urine in unchanged form.

Spectinomycin dihydrochloride pentahydrate selectively inhibits protein synthesis in cells and in extracts of Escherichia coli: Spectinomycin dihydrochloride pentahydrate (50 μg/mL) inhibits Escherichia coli growth rapidly and reversibly, and suppresses amino acid incorporation immediately. Spectinomycin dihydrochloride pentahydrate (1 μg/mL or 3 μM) inhibits polypeptide synthesis directed either by endogenous messenger RNA or by MS-2 bacteriophage RNA, with maximum inhibition of 70-80% in extracts of Escherichia coli. Spectinomycin dihydrochloride pentahydrate blocks the translocation of peptidyl-tRNAs from A-site to P-site by inhibiting the binding of elongation factor G to the ribosome. Spectinomycin dihydrochloride pentahydrate interacts specifically with the residues G1064 and 01192 in 16S rRNA and potentially makes it inactive.Spectinomycin dihydrochloride pentahydrate exhibits splicing inhibition and dependent on pH changes and Mg2+ concentration, indicating electrostatic interactions with the intron RNA.

Spectinomycin dihydrochloride pentahydrate (20 mg/kg; i.m.; 20-100 mg/kg; 9 d) shows the safety in healthy chicks.Spectinomycin dihydrochloride pentahydrate (10 mg/kg; i.v.; single dose) has the major elimination pathway by renal excretion, approximately 55% is excreted into the urine in unchanged form.Pharmacokinetics of Spectinomycin dihydrochloride pentahydrate in Rat.Animal Model:Arbor Acres plus broiler chicks (15-day-old)Dosage:20 mg/kg, 60 mg/kg, 100 mg/kg Administration:Intramuscular injection (chest muscles); 9 days Result:Showed biosecurity of 20 mg/kg by complete blood count, biochemical parameters, histopathological, clinical signs, body weight gain, and feed conversion ratio (FCR).Resulted minor toxicity of 60 mg/kg.

Spectinomycin hydrochloride hydrate

Endocrinology/Hormones

Opioid Receptor

30S ribosome

Infection

——

22189-32-8

495.35

C14H24N2O7·2HCl·5H2O

>98% (HPLC)

H2O : ≥ 6.6 mg/mL; 13.32 mM

O.O.O.O.O.Cl.Cl.CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O

——

(-20℃)

With Ice Pack

≥ 2 years